Clinical significance of bronchial reversibility test in the treatment of childhood asthma

LI Yun, LIU Dan, YI Hong-Ling, GUO Chun, CHEN Min, LI Wen-Kai

Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (2) : 105-108.

PDF(928 KB)
PDF(928 KB)
Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (2) : 105-108. DOI: 10.7499/j.issn.1008-8830.2013.02.008
CLINICAL RESEARCH

Clinical significance of bronchial reversibility test in the treatment of childhood asthma

  • LI Yun, LIU Dan, YI Hong-Ling, GUO Chun, CHEN Min, LI Wen-Kai
Author information +
History +

Abstract

OBJECTIVE: To observe changes in the lung function of asthmatic children with different symptoms during treatment, and to investigate the clinical significance of bronchial reversibility test in the treatment of asthma in children. METHODS: A total of 417 asthmatic children were treated by salmeterol/fluticasone inhalation for more than 3 months. These patients were divided into asymptomatic, single cough, paroxysmal cough and wheeze (cough+wheeze or wheeze alone) groups based on the symptoms when they revisited the clinic. Thirty-four healthy children were used as a control group. All children underwent bronchial reversibility test using nebulized salbutamol. Lung function testing was performed before and after the test. RESULTS: After nebulization of salbutamol, each asthma group showed significantly decreased rate of abnormal lung function and significantly increased forced expiratory volume in one second percent (FEV1%) predicted (P<0.05). Before salbutamol nebulization, the single cough, paroxysmal cough and wheeze groups had significantly higher rates of abnormal lung function and significantly lower FEV1% predicted than the control group (P<0.05). There were significant differences in the rate of abnormal lung function and FEV1% predicted among the asthma groups (P<0.05). After salbutamol nebulization, the paroxysmal cough and wheeze groups had significantly higher rates of abnormal lung function than the control group (P<0.05), but there were no significant differences between other asthma and control groups; the wheeze group had significantly lower FEV1% predicted than the control group, but no significant differences were found between other asthma and the control groups. The positive rate of bronchial reversibility test in each asthma group was significantly higher than in the control group (P<0.05). There were significant differences in the positive rate of the test between the asthma groups except between the asymptomatic and single cough groups (P<0.05). CONCLUSIONS: Asthmatic children with different symptoms demonstrate different lung functions during treatment. Bronchial reversibility test combined with lung function test is useful in assessing asthma control and guiding treatment.

Key words

Asthma / Bronchodilator reversibility test / Lung function / Salbutamol / Child

Cite this article

Download Citations
LI Yun, LIU Dan, YI Hong-Ling, GUO Chun, CHEN Min, LI Wen-Kai. Clinical significance of bronchial reversibility test in the treatment of childhood asthma[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(2): 105-108 https://doi.org/10.7499/j.issn.1008-8830.2013.02.008

References

[1]安淑华,李金英,赵清娟,郑博娟,王艳艳,王宁,等. 常规肺通气功能检测在儿童支气管哮喘诊疗中的作用[J]. 实用儿科临床杂志,2011,26 (4): 257-259.

[2]洪建国.儿童支气管哮喘的诊断治疗:实用变态反应学共识报告[J].实用儿科临床杂志,2009,24(16):1297-1300.

[3]潘频华,陈清兰,胡成平,吴鄂生,尹本义.长期吸入糖皮质激素对哮喘患者肺功能的影响[J].中国医学工程,2007,15(6):515-517.

[4]郁志伟,谢娟娟,钱俊,潘剑蓉,张晓娟,项红霞.体外过敏原与脉冲振荡肺功能测定在儿童咳嗽变异性哮喘中的作用[J].中国当代儿科杂志,2011,13(7):554-557.

[5]马金海,刘静,刘玢. 沙美特罗/丙酸氟替卡松联合布地奈德治疗支气管哮喘[J].实用儿科临床杂志,2011,26 (21):1673-1674.

[6]Zielen S, Christmann M, Kloska M, Dogan-Yildiz G, Lieb A, Rosewich M, et al. Predicting short term response to anti-inflammatory therapy in young children with asthma[J]. Curr Med Res Opin, 2010, 26(2): 483-492.

[7]Kjaer HF, Eller E, Bindslev-Jensen C. Spirometry in an unselected group of 6-year-old children: the DARC birth cohort study[J].Pediatr Pulmonol, 2008, 43(8): 806-814.

[8]Naimi DR, Freedman TG, Ginsburg KR, Bogen D, Rand CS, Apter AJ. Adolescents and asthma: Why bother with our meds?[J]. J Allergy Clin Immunol, 2009, 123(6): 1335-1341.

[9]Sundberg R, Palmqvist M, Tunsater A. Health-related quality of life in young adults with asthma[J]. Respir Med, 2009, 103(10): 1580-1585.

[10]Iramain R, López-Herce J, Coronel J, Spitters C, Guggiari J, Bogado N.Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children[J]. J Asthma, 2011, 48(3): 298-303.

[11]Borg BM, Reid DW, Walters EH, Johns DP. Bronchodilator reversibility testing: laboratory practices in Australia and New Zealand[J]. Med J Aust, 2004, 180 (12): 610-613.

[12]Lehmann S, Bakke PS, Eide GE, Humerfelt S, Gulsvik A. Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a β2-agonist[J]. Pulm Pharmacol Ther, 2006, 19 (4): 272-280.

[13]Walters EH, Walters JA, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma[J]. Cochrane Database Syst Rev, 2002, (4): CD003901.

PDF(928 KB)

Accesses

Citation

Detail

Sections
Recommended

/